# Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01331694** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 76130 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** fluticasone/salmeterol combination (FSC) 250/50mcg
- **DRUG:** tiotropium
- **DRUG:** ipratropium bromide alone or in fixed dose combination with albuterol

## Key facts

- **NCT ID:** NCT01331694
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 76130 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01331694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01331694, "Outcomes and Costs Associated With Initiating Maintenance Treatment With Fluticasone Propionate 250mcg/Salmeterol Xinafoate 50mcg Combination (FSC) Versus Anticholinergics Including Tiotropium (TIO) in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01331694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*